Jesse J Waggoner1, Alejandra Rojas2, Alisha Mohamed-Hadley3, Yvalena Arévalo de Guillén2, Benjamin A Pinsky4. 1. Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA; Department of Global Health, Rollins School of Public Health, Atlanta, GA, USA. Electronic address: jesse.j.waggoner@emory.edu. 2. Departamento de Producción, Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, Asunción, Paraguay. 3. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. 4. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, USA.
Abstract
BACKGROUND: Mayaro virus (MAYV) causes an acute febrile illness which can be difficult to differentiate from dengue or chikungunya. MAYV RNA can be detected in plasma during the first 3-5days of illness, but only a single rRT-PCR has been fully evaluated in the literature. OBJECTIVES: To develop an rRT-PCR for MAYV and evaluate assay performance using human plasma and urine samples spiked with different MAYV strains. STUDY DESIGN: A MAYV rRT-PCR targeting a region of the 5'UTR and nsp1 gene was designed from the alignment of all complete-genome MAYV sequences to be compatible with existing laboratory protocols. The assay was evaluated using human samples spiked with six MAYV strains, including strains from each of the three genotypes. RESULTS: The linear range of the MAYV rRT-PCR extended from 1.0 to 8.0 log10copies/μL, and the lower limit of 95% detection was 8.2copies/μL. No detection was observed when the MAYV rRT-PCR was tested with genomic RNA from related arboviruses. The assay demonstrated linear amplification of all 6 MAYV strains when spiked into human plasma samples as well as 2 strains spiked into urine. CONCLUSIONS: We report the design and evaluation of an rRT-PCR for MAYV. Given the concern for MAYV emergence in the Americas and the few molecular tests that have been evaluated in the literature, this assay should provide a useful diagnostic for patients with an acute febrile illness.
BACKGROUND:Mayaro virus (MAYV) causes an acute febrile illness which can be difficult to differentiate from dengue or chikungunya. MAYV RNA can be detected in plasma during the first 3-5days of illness, but only a single rRT-PCR has been fully evaluated in the literature. OBJECTIVES: To develop an rRT-PCR for MAYV and evaluate assay performance using human plasma and urine samples spiked with different MAYV strains. STUDY DESIGN: A MAYV rRT-PCR targeting a region of the 5'UTR and nsp1 gene was designed from the alignment of all complete-genome MAYV sequences to be compatible with existing laboratory protocols. The assay was evaluated using human samples spiked with six MAYV strains, including strains from each of the three genotypes. RESULTS: The linear range of the MAYV rRT-PCR extended from 1.0 to 8.0 log10copies/μL, and the lower limit of 95% detection was 8.2copies/μL. No detection was observed when the MAYV rRT-PCR was tested with genomic RNA from related arboviruses. The assay demonstrated linear amplification of all 6 MAYV strains when spiked into human plasma samples as well as 2 strains spiked into urine. CONCLUSIONS: We report the design and evaluation of an rRT-PCR for MAYV. Given the concern for MAYV emergence in the Americas and the few molecular tests that have been evaluated in the literature, this assay should provide a useful diagnostic for patients with an acute febrile illness.
Authors: Roberta V M Bronzoni; Marcos L Moreli; Ana Cecília R Cruz; Luiz Tadeu M Figueiredo Journal: Trans R Soc Trop Med Hyg Date: 2004-08 Impact factor: 2.184
Authors: Kanya C Long; Sarah A Ziegler; Saravanan Thangamani; Nicole L Hausser; Tadeusz J Kochel; Stephen Higgs; Robert B Tesh Journal: Am J Trop Med Hyg Date: 2011-10 Impact factor: 2.345
Authors: F P Pinheiro; R B Freitas; J F Travassos da Rosa; Y B Gabbay; W A Mello; J W LeDuc Journal: Am J Trop Med Hyg Date: 1981-05 Impact factor: 2.345
Authors: Albert J Auguste; Jonathan Liria; Naomi L Forrester; Dileyvic Giambalvo; Maria Moncada; Kanya C Long; Dulce Morón; Nuris de Manzione; Robert B Tesh; Eric S Halsey; Tadeusz J Kochel; Rosa Hernandez; Juan-Carlos Navarro; Scott C Weaver Journal: Emerg Infect Dis Date: 2015-10 Impact factor: 6.883
Authors: Eric S Halsey; Crystyan Siles; Carolina Guevara; Stalin Vilcarromero; Erik J Jhonston; Cesar Ramal; Patricia V Aguilar; Julia S Ampuero Journal: Emerg Infect Dis Date: 2013-11 Impact factor: 6.883
Authors: Barbara Friedrich-Jänicke; Petra Emmerich; Dennis Tappe; Stephan Günther; Daniel Cadar; Jonas Schmidt-Chanasit Journal: Emerg Infect Dis Date: 2014-07 Impact factor: 6.883
Authors: Arthur S Kim; Natasha M Kafai; Emma S Winkler; Theron C Gilliland; Emily L Cottle; James T Earnest; Prashant N Jethva; Paulina Kaplonek; Aadit P Shah; Rachel H Fong; Edgar Davidson; Ryan J Malonis; Jose A Quiroz; Lauren E Williamson; Lo Vang; Matthias Mack; James E Crowe; Benjamin J Doranz; Jonathan R Lai; Galit Alter; Michael L Gross; William B Klimstra; Daved H Fremont; Michael S Diamond Journal: Cell Date: 2021-08-19 Impact factor: 66.850
Authors: Cormac J Lucas; Bennett J Davenport; Kathryn S Carpentier; Alex N Tinega; Thomas E Morrison Journal: J Virol Date: 2022-04-13 Impact factor: 6.549
Authors: James T Earnest; Katherine Basore; Vicky Roy; Adam L Bailey; David Wang; Galit Alter; Daved H Fremont; Michael S Diamond Journal: J Exp Med Date: 2019-07-23 Impact factor: 14.307
Authors: James T Earnest; Autumn C Holmes; Katherine Basore; Matthias Mack; Daved H Fremont; Michael S Diamond Journal: Cell Rep Date: 2021-04-06 Impact factor: 9.423